CM Life Sciences III Inc.
CMLT
NASDAQ Capital Market8.69
USD
-0.52
- -
CIK
0001843762
ISIN
US1258411065
CUSIP
125841106
Return %
Stock
S&P500
1Y
- -
18.21
3Y
-13.79
64.38
5Y
-13.79
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 667 Madison Avenue New York City NY United States of America 10065
- IPO Date
- Apr 7, 2021
- CIK
- 0001843762
- Website
- iii.cmlifesciencesspac.com
- Similar Companies
- Business
- CM Life Sciences III Inc. (CMLT) operates as a blank check company, or special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, with a focus on the life sciences sector including life sciences tools, synthetic biology and diagnostics; it offers no current products or services beyond its standard SPAC structure of cash held in trust for a potential target acquisition. The company, sponsored by affiliates of Casdin Capital LLC and Corvex Management LP, is led by Chief Executive Officer Eli Casdin and Chairman Keith Meister, and targets fragmented areas within life sciences where consolidation opportunities exist for under-resourced innovative companies. Founded in 2020 and headquartered in New York, it conducts operations primarily in the United States through its Nasdaq-listed Class A common stock and warrants. In 2021, the company announced and pursued a definitive business combination agreement with EQRx Inc., a pharmaceutical developer aiming to deliver medicines at lower prices, valued at up to $3.65 billion including a potential $500 million earnout, with shareholder approval obtained in December 2021; however, the merger did not proceed to completion and no subsequent business combination or liquidation has been finalized as of late 2025, leaving CMLT as an inactive instrument with minimal cash reserves, a significant working capital deficit and shares trading at low values.
EQRx Goes Public
Corvex, Casdin Backed SPAC To Merge With EQRx In $1.8B Deal